Grifols, ES0171996087

Grifols stock slips as market cap and peers stay under pressure

Published on 09/02/2026 at 15:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Grifols stock traded at EUR 9.95 on August 7, 2026, while MarketBeat showed a USD 5.23 billion market value and a 52-week range of USD 6.96 to USD 10.23.

3D-Architekturrender eines modernen Biotech-Forschungscampus mit Glasfassade — Architektur-Render eines modernen Forschungscampus visualisiert die Infrastruktur von Grifols S.A. ES0171996087 im Biotech-Sektor, Illustration mit AI erstellt.

Grifols (ISIN ES0171996087) traded at EUR 9.95 on August 7, 2026, after a 1.00 percent drop, while the company sat at a EUR 6.774 billion market cap in the same snapshot. The latest available price-and-statistics pages also show a 52-week range of USD 6.96 to USD 10.23 on the US listing and volume of 322,332 shares as of August 28, 2026.

Market values on the board

On the US line, MarketBeat put Grifols at USD 7.69 on August 28, 2026, with a market capitalization of USD 5.23 billion and a consensus price target of USD 10.00. That implies an upside gap of 30.0 percent from the quoted price.

Reuters said European shares were pinned near a one-month low on September 2, 2026, as higher bond yields weighed on sentiment across the region. Grifols moved within that softer backdrop, which matters because the stock is sensitive to risk appetite as well as the companys own operating numbers.

Revenue still matters most

MarketScreener listed net sales of EUR 7.212 billion and capitalization of EUR 7.437 billion for Grifols, with 23,833 employees in its basic data view. Those figures frame the stock around a business that still operates on a large scale even as investors focus on leverage and cash generation.

The same MarketScreener page also showed sales per employee of EUR 302,622, a ratio that gives a simple read on operating efficiency. For investors, that is one of the cleaner comparables when the share price and market value are moving faster than the fundamental story.

Go deeper

Grifols shares and the latest market data

Key figures, recent trading levels and the companys operating base in one view.

Grifols overview Investor Relations

Blood plasma remains core

Grifols builds its business around plasma-derived medicines, which is why sales, margins and cash conversion stay central to the stock story. The latest quoted sales base of EUR 7.212 billion and the 23,833-employee footprint show the scale behind that model.

Closing stock view

Grifols stock last traded at EUR 9.95 on August 7, 2026, with the US listing at USD 7.69 on August 28, 2026. The gap between those trading levels and the USD 10.00 consensus target on MarketBeat keeps the valuation debate open.